These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 25934423)

  • 1. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
    Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
    BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily.
    Capra G; Giovannelli L; Matranga D; Bellavia C; Guarneri MF; Fasciana T; Scaduto G; Firenze A; Vassiliadis A; Perino A
    Hum Vaccin Immunother; 2017 Aug; 13(8):1839-1843. PubMed ID: 28594305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
    Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
    Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
    Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
    Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
    Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
    J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis.
    Palmer M; Katanoda K; Saito E; Acuti Martellucci C; Tanaka S; Ikeda S; Sakamoto H; Machelek D; Ml Brotherton J; Hocking JS
    Vaccine; 2022 Sep; 40(41):5971-5996. PubMed ID: 36085257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study.
    Prétet JL; Jacquard AC; Saunier M; Clavel C; Dachez R; Gondry J; Pradat P; Soubeyrand B; Leocmach Y; Mougin C; Riethmuller D;
    Gynecol Oncol; 2008 Aug; 110(2):179-84. PubMed ID: 18514800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
    Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
    Boiron L; Joura E; Largeron N; Prager B; Uhart M
    BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S; Gasparini R; Panatto D; Demarteau N
    Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
    Borracci RA; Segal SV; Méndez JH
    Medicina (B Aires); 2018; 78(5):315-328. PubMed ID: 30285924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
    Pitisuttithum P; Velicer C; Luxembourg A
    Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic human papillomavirus vaccines: past, present and future.
    Anderson LA
    Pathology; 2012 Jan; 44(1):1-6. PubMed ID: 22157686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis.
    Bogaards JA; Wallinga J; Brakenhoff RH; Meijer CJ; Berkhof J
    BMJ; 2015 May; 350():h2016. PubMed ID: 25985328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expected impact of a quadrivalent HPV vaccine in France].
    Riethmuller D; Prétet JL; Denis F; Aubin F; Pradat P; Clavel C; Dachez R; Gondry J; Carcopino X; Mougin C
    J Gynecol Obstet Biol Reprod (Paris); 2009 Sep; 38(5):389-95. PubMed ID: 19481365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HPV infection in males: an update.
    Giraldi G; De Luca d'Alessandro E
    Ann Ig; 2012; 24(6):497-506. PubMed ID: 23234187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Papillomavirus, could we speak about cancer and prevention?].
    Pernot S; Pavie J; Péré H; Menard M; Hurel S; Cochand-Priollet B; Bats AS; Badoual C
    Bull Cancer; 2018 Feb; 105(2):137-139. PubMed ID: 29373106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.